In the TCGA data set, the incidence of FLT3 amplification was highest in colorectal cancer (34.6%), breast cancer (10.5%), and gastric cancer (8.3%) in the order of frequency in all FLT3-amplified cancer (Supplementary Figure S1). The gene discussed is FLT3; the disease is gastric cancer.